{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:51:56Z","timestamp":1792173116770,"version":"4.4.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-71093-9","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T04:04:08Z","timestamp":1774497848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations"],"prefix":"10.1038","volume":"17","author":[{"given":"Jianxiong","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0859-3923","authenticated-orcid":false,"given":"Tongzheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0619-1173","authenticated-orcid":false,"given":"Yi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0433-2147","authenticated-orcid":false,"given":"Zhengqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"71093_CR1","doi-asserted-by":"crossref","unstructured":"Reiner, D. J. & Lundquist, E. A. Small GTPases. WormBook 2018, 1\u201365 (2018).","DOI":"10.1895\/wormbook.1.67.2"},{"key":"71093_CR2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/304596a0","volume":"304","author":"H Land","year":"1983","unstructured":"Land, H., Parada, L. F. & Weinberg, R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596\u2013602 (1983).","journal-title":"Nature"},{"key":"71093_CR3","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1242\/jcs.182873","volume":"129","author":"GA Hobbs","year":"2016","unstructured":"Hobbs, G. A., Der, C. J. & Rossman, K. L. RAS isoforms and mutations in cancer at a glance. J. Cell Sci. 129, 1287\u20131292 (2016).","journal-title":"J. Cell Sci."},{"key":"71093_CR4","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","volume":"13","author":"JC Hunter","year":"2015","unstructured":"Hunter, J. C. et al. Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol. Cancer Res. 13, 1325\u20131335 (2015).","journal-title":"Mol. Cancer Res."},{"key":"71093_CR5","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.3390\/cancers13225599","volume":"13","author":"HJ Kim","year":"2021","unstructured":"Kim, H. J. et al. Oncogenic KRAS: signaling and drug resistance. Cancers 13, 5599 (2021).","journal-title":"Cancers"},{"key":"71093_CR6","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41568-018-0076-6","volume":"18","author":"S Li","year":"2018","unstructured":"Li, S., Balmain, A. & Counter, C. M. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat. Rev. Cancer 18, 767\u2013777 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"71093_CR7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1126\/science.2406906","volume":"247","author":"MV Milburn","year":"1990","unstructured":"Milburn, M. V. et al. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 247, 939\u2013945 (1990).","journal-title":"Science"},{"key":"71093_CR8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem, J. M. et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548\u2013551 (2013).","journal-title":"Nature"},{"key":"71093_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17\u201333 (2017).","journal-title":"Cell"},{"key":"71093_CR10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","volume":"39","author":"J Timar","year":"2020","unstructured":"Timar, J. & Kashofer, K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 39, 1029\u20131038 (2020).","journal-title":"Cancer Metastasis Rev."},{"key":"71093_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"71093_CR12","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"71093_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin, J. et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of kras-mutant cancers in mouse models and patients. Cancer Discov. 10, 54\u201371 (2020).","journal-title":"Cancer Discov."},{"key":"71093_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N. Engl. J. Med. 387, 120\u2013131 (2022).","journal-title":"N. Engl. J. Med."},{"key":"71093_CR15","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/s41591-024-03401-z","volume":"31","author":"Y Shi","year":"2025","unstructured":"Shi, Y. et al. Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial. Nat. Med. 31, 894\u2013900 (2025).","journal-title":"Nat. Med."},{"key":"71093_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","volume":"29","author":"J Liu","year":"2022","unstructured":"Liu, J., Kang, R. & Tang, D. The KRAS-G12C inhibitor: activity and resistance. Cancer Gene Ther. 29, 875\u2013878 (2022).","journal-title":"Cancer Gene Ther."},{"key":"71093_CR17","doi-asserted-by":"publisher","first-page":"e155523","DOI":"10.1172\/JCI155523","volume":"132","author":"YS Tsai","year":"2022","unstructured":"Tsai, Y. S. et al. Rapid idiosyncratic mechanisms of clinical resistance to KRASG12C inhibition. J. Clin. Invest. 132, e155523 (2022).","journal-title":"J. Clin. Invest."},{"key":"71093_CR18","doi-asserted-by":"publisher","first-page":"S373","DOI":"10.1016\/j.annonc.2022.04.437","volume":"33","author":"H Prenen","year":"2022","unstructured":"Prenen, H. et al. SO-39 evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: exploratory plasma biomarker analysis of CodeBreaK 100. Ann. Oncol. 33, S373 (2022).","journal-title":"Ann. Oncol."},{"key":"71093_CR19","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","volume":"16","author":"T Koga","year":"2021","unstructured":"Koga, T. et al. KRAS secondary mutations that confer acquired resistance to KRASG12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. J. Thorac. Oncol. 16, 1321\u20131332 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"71093_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/2159-8290.CD-20-1616","volume":"11","author":"NS Akhave","year":"2021","unstructured":"Akhave, N. S., Biter, A. B. & Hong, D. S. Mechanisms of resistance to KRASG12C-targeted therapy. Cancer Discov. 11, 1345\u20131352 (2021).","journal-title":"Cancer Discov."},{"key":"71093_CR21","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1158\/1538-7445.AM2023-1649","volume":"83","author":"KP Foley","year":"2023","unstructured":"Foley, K. P. et al. Chemically induced chaperone-mediated protein degradation (CHAMP) of KRAS(G12C). Cancer Res. 83, 1649 (2023).","journal-title":"Cancer Res."},{"key":"71093_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00834-2","volume":"20","author":"RH Gong","year":"2022","unstructured":"Gong, R. H. et al. Combination of artesunate and WNT974 induces KRAS protein degradation by upregulating E3 ligase ANACP2 and \u03b2-TrCP in the ubiquitin-proteasome pathway. Cell Commun. Signal. 20, 34 (2022).","journal-title":"Cell Commun. Signal."},{"key":"71093_CR23","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1126\/science.adm8684","volume":"385","author":"J Popow","year":"2024","unstructured":"Popow, J. et al. Targeting cancer with small-molecule pan-KRAS degraders. Science 385, 1338\u20131347 (2024).","journal-title":"Science"},{"key":"71093_CR24","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA 98, 8554\u20138559 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71093_CR25","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/D2CS00193D","volume":"51","author":"K Li","year":"2022","unstructured":"Li, K. & Crews, C. M. PROTACs: past, present and future. Chem. Soc. Rev. 51, 5214\u20135236 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"71093_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1021\/jacs.1c03980","volume":"144","author":"NJ Henning","year":"2022","unstructured":"Henning, N. J. et al. Discovery of a covalent FEM1B recruiter for targeted protein degradation applications. J. Am. Chem. Soc. 144, 701\u2013708 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"71093_CR27","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.chembiol.2021.04.011","volume":"28","author":"KTG Samarasinghe","year":"2021","unstructured":"Samarasinghe, K. T. G. & Crews, C. M. Targeted protein degradation: a promise for undruggable proteins. Cell Chem. Biol. 28, 934\u2013951 (2021).","journal-title":"Cell Chem. Biol."},{"key":"71093_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","volume":"64","author":"V Oleinikovas","year":"2024","unstructured":"Oleinikovas, V. et al. From thalidomide to rational molecular glue design for targeted protein degradation. Annu. Rev. Pharmacol. Toxicol. 64, 291\u2013312 (2024).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"71093_CR29","doi-asserted-by":"publisher","first-page":"7201","DOI":"10.1038\/onc.2008.320","volume":"27","author":"A Rodriguez-Gonzalez","year":"2008","unstructured":"Rodriguez-Gonzalez, A. et al. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene 27, 7201\u20137211 (2008).","journal-title":"Oncogene"},{"key":"71093_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2174\/1386207043328364","volume":"7","author":"D Zhang","year":"2004","unstructured":"Zhang, D. et al. Targeted degradation of proteins by small molecules: a novel tool for functional proteomics. Comb. Chem. High. Throughput Screen. 7, 689\u2013697 (2004).","journal-title":"Comb. Chem. High. Throughput Screen."},{"key":"71093_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02216-3","volume":"24","author":"Y Shi","year":"2025","unstructured":"Shi, Y. et al. Targeting KRAS: from metabolic regulation to cancer treatment. Mol. Cancer 24, 9 (2025).","journal-title":"Mol. Cancer"},{"key":"71093_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.chembiol.2019.12.006","volume":"27","author":"M Zeng","year":"2020","unstructured":"Zeng, M. et al. Exploring targeted degradation strategy for oncogenic KRASG12C. Cell Chem. Biol. 27, 19\u201331 (2020).","journal-title":"Cell Chem. Biol."},{"key":"71093_CR33","doi-asserted-by":"publisher","first-page":"114088","DOI":"10.1016\/j.ejmech.2021.114088","volume":"230","author":"F Yang","year":"2022","unstructured":"Yang, F. et al. Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC. Eur. J. Med. Chem. 230, 114088 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"71093_CR34","doi-asserted-by":"publisher","first-page":"115857","DOI":"10.1016\/j.ejmech.2023.115857","volume":"261","author":"N Yang","year":"2023","unstructured":"Yang, N. et al. Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-mutation. Eur. J. Med. Chem. 261, 115857 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"71093_CR35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/17460441.2023.2187047","volume":"18","author":"H Yokoo","year":"2023","unstructured":"Yokoo, H., Naito, M. & Demizu, Y. Investigating the cell permeability of proteolysis-targeting chimeras (PROTACs). Expert Opin. Drug Discov. 18, 357\u2013361 (2023).","journal-title":"Expert Opin. Drug Discov."},{"key":"71093_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49739-3","volume":"15","author":"C Kagiou","year":"2024","unstructured":"Kagiou, C. et al. Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation. Nat. Commun. 15, 5409 (2024).","journal-title":"Nat. Commun."},{"key":"71093_CR37","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1038\/s41589-024-01655-9","volume":"20","author":"AA Basu","year":"2024","unstructured":"Basu, A. A. et al. A CRISPR activation screen identifies FBXO22 supporting targeted protein degradation. Nat. Chem. Biol. 20, 1608\u20131616 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"71093_CR38","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1021\/acscentsci.4c00286","volume":"10","author":"M Lim","year":"2024","unstructured":"Lim, M. et al. DCAF16-based covalent handle for the rational design of monovalent degraders. ACS Cent. Sci. 10, 1318\u20131331 (2024).","journal-title":"ACS Cent. Sci."},{"key":"71093_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.chembiol.2023.01.004","volume":"30","author":"J Pei","year":"2023","unstructured":"Pei, J. et al. Piperlongumine conjugates induce targeted protein degradation. Cell Chem. Biol. 30, 203\u2013213 (2023).","journal-title":"Cell Chem. Biol."},{"key":"71093_CR40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1021\/acschembio.2c00747","volume":"18","author":"AG Shergalis","year":"2023","unstructured":"Shergalis, A. G. et al. CRISPR screen reveals BRD2\/4 molecular glue-like degrader via recruitment of DCAF16. ACS Chem. Biol. 18, 331\u2013339 (2023).","journal-title":"ACS Chem. Biol."},{"key":"71093_CR41","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1021\/jacs.1c00990","volume":"143","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. DCAF11 supports targeted protein degradation by electrophilic proteolysis-targeting chimeras. J. Am. Chem. Soc. 143, 5141\u20135149 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"71093_CR42","doi-asserted-by":"publisher","first-page":"18688","DOI":"10.1021\/jacs.2c08964","volume":"144","author":"Y Tao","year":"2022","unstructured":"Tao, Y. et al. Targeted protein degradation by electrophilic PROTACs that stereoselectively and site-specifically engage DCAF1. J. Am. Chem. Soc. 144, 18688\u201318699 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"71093_CR43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.chembiol.2021.01.005","volume":"28","author":"M Luo","year":"2021","unstructured":"Luo, M. et al. Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function. Cell Chem. Biol. 28, 559\u2013566 (2021).","journal-title":"Cell Chem. Biol."},{"key":"71093_CR44","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41589-024-01668-4","volume":"20","author":"YD Li","year":"2024","unstructured":"Li, Y. D. et al. Template-assisted covalent modification underlies activity of covalent molecular glues. Nat. Chem. Biol. 20, 1640\u20131649 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"71093_CR45","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41589-019-0304-8","volume":"15","author":"JN Spradlin","year":"2019","unstructured":"Spradlin, J. N. et al. Harnessing the anti-cancer natural product nimbolide for targeted protein degradation. Nat. Chem. Biol. 15, 747\u2013755 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"71093_CR46","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41589-019-0279-5","volume":"15","author":"X Zhang","year":"2019","unstructured":"Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M. & Cravatt, B. F. Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16. Nat. Chem. Biol. 15, 737\u2013746 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"71093_CR47","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/s41589-024-01660-y","volume":"20","author":"DY Nie","year":"2024","unstructured":"Nie, D. Y. et al. Recruitment of FBXO22 for targeted degradation of NSD2. Nat. Chem. Biol. 20, 1597\u20131607 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"71093_CR48","doi-asserted-by":"publisher","first-page":"21512","DOI":"10.1021\/jacs.4c18083","volume":"147","author":"X He","year":"2025","unstructured":"He, X. et al. Covalent recruitment of NEDD4 for targeted protein degradation: rational design of small molecular degraders. J. Am. Chem. Soc. 147, 21512\u201321525 (2025).","journal-title":"J. Am. Chem. Soc."},{"key":"71093_CR49","doi-asserted-by":"crossref","unstructured":"Ouyang, X. et al. Proteome-wide ligand and target discovery by using \u03b2-nitrostyrene electrophiles: supporting targeted protein degradation. Angew. Chem. Int. Ed. 64, e202504813 (2025).","DOI":"10.1002\/anie.202504813"},{"key":"71093_CR50","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1021\/acs.jmedchem.3c02123","volume":"67","author":"RR Shah","year":"2024","unstructured":"Shah, R. R. et al. Structure-guided design and optimization of covalent VHL-targeted sulfonyl fluoride PROTACs. J. Med. Chem. 67, 4641\u20134654 (2024).","journal-title":"J. Med. Chem."},{"key":"71093_CR51","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/s41557-023-01304-z","volume":"15","author":"Z Qin","year":"2023","unstructured":"Qin, Z. et al. Discovering covalent inhibitors of protein-protein interactions from trillions of sulfur(VI) fluoride exchange-modified oligonucleotides. Nat. Chem. 15, 1705\u20131714 (2023).","journal-title":"Nat. Chem."},{"key":"71093_CR52","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1021\/jacs.6b08536","volume":"139","author":"Q Zhao","year":"2017","unstructured":"Zhao, Q. et al. Broad-spectrum kinase profiling in live cells with lysine-targeted sulfonyl fluoride probes. J. Am. Chem. Soc. 139, 680\u2013685 (2017).","journal-title":"J. Am. Chem. Soc."},{"key":"71093_CR53","doi-asserted-by":"publisher","first-page":"20403","DOI":"10.1021\/jacs.3c05899","volume":"145","author":"Z Yu","year":"2023","unstructured":"Yu, Z. et al. Simultaneous covalent modification of K-Ras(G12D) and K-Ras(G12C) with tunable oxirane electrophiles. J. Am. Chem. Soc. 145, 20403\u201320411 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"71093_CR54","doi-asserted-by":"publisher","first-page":"117902","DOI":"10.1016\/j.bmc.2024.117902","volume":"112","author":"L Liang","year":"2024","unstructured":"Liang, L., Zhang, Z., You, Q. & Guo, X. Recent advances in the design of small molecular drugs with acrylamides covalent warheads. Bioorg. Med. Chem. 112, 117902 (2024).","journal-title":"Bioorg. Med. Chem."},{"key":"71093_CR55","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1021\/acs.orglett.2c01410","volume":"24","author":"T Scattolin","year":"2022","unstructured":"Scattolin, T., Gharbaoui, T. & Chen, C. Y. A nucleophilic deprotection of carbamate mediated by 2-mercaptoethanol. Org. Lett. 24, 3736\u20133740 (2022).","journal-title":"Org. Lett."},{"key":"71093_CR56","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1021\/acs.oprd.2c00386","volume":"27","author":"DR Snead","year":"2023","unstructured":"Snead, D. R. et al. Development of Adagrasib\u2019s commercial manufacturing route. Org. Process Res. Dev. 27, 530\u2013538 (2023).","journal-title":"Org. Process Res. Dev."},{"key":"71093_CR57","unstructured":"RayzeBio Inc. et al. Conjugates Comprising Covalent Binders for Targeting Intracellular KRASG12C Proteins, WIPO, WO2023014979 (2023)."},{"key":"71093_CR58","doi-asserted-by":"publisher","first-page":"116386","DOI":"10.1016\/j.bmc.2021.116386","volume":"47","author":"N Shindo","year":"2021","unstructured":"Shindo, N. & Ojida, A. Recent progress in covalent warheads for in vivo targeting of endogenous proteins. Bioorg. Med. Chem. 47, 116386 (2021).","journal-title":"Bioorg. Med. Chem."},{"key":"71093_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39268-w","volume":"14","author":"TY Koo","year":"2023","unstructured":"Koo, T. Y. et al. N-Acryloylindole-alkyne (NAIA) enables imaging and profiling new ligandable cysteines and oxidized thiols by chemoproteomics. Nat. Commun. 14, 3564 (2023).","journal-title":"Nat. Commun."},{"key":"71093_CR60","doi-asserted-by":"publisher","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","volume":"63","author":"JB Fell","year":"2020","unstructured":"Fell, J. B. et al. Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer. J. Med. Chem. 63, 6679\u20136693 (2020).","journal-title":"J. Med. Chem."},{"key":"71093_CR61","doi-asserted-by":"publisher","first-page":"273","DOI":"10.37349\/etat.2020.00018","volume":"1","author":"RI Troup","year":"2020","unstructured":"Troup, R. I. et al. Current strategies for the design of PROTAC linkers: a critical review. Explor. Target Antitumor Ther. 1, 273\u2013312 (2020).","journal-title":"Explor. Target Antitumor Ther."},{"key":"71093_CR62","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","volume":"6","author":"MJ Bond","year":"2020","unstructured":"Bond, M. J. et al. Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs. ACS Cent. Sci. 6, 1367\u20131375 (2020).","journal-title":"ACS Cent. Sci."},{"key":"71093_CR63","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/emmm.201202341","volume":"5","author":"D Cepeda","year":"2013","unstructured":"Cepeda, D. et al. CDK-mediated activation of the SCF(FBXO28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol. Med. 5, 1067\u20131086 (2013).","journal-title":"EMBO Mol. Med."},{"key":"71093_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-022-00433-3","volume":"11","author":"E Phillips","year":"2022","unstructured":"Phillips, E. et al. PFKFB4 interacts with FBXO28 to promote HIF-1\u03b1 signaling in glioblastoma. Oncogenesis 11, 57 (2022).","journal-title":"Oncogenesis"},{"key":"71093_CR65","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1038\/s41388-023-02809-0","volume":"42","author":"X Qiao","year":"2023","unstructured":"Qiao, X. et al. FBXO28 suppresses liver cancer invasion and metastasis by promoting PKA-dependent SNAI2 degradation. Oncogene 42, 2878\u20132891 (2023).","journal-title":"Oncogene"},{"key":"71093_CR66","unstructured":"Wang, X., Lawson, J. D. & Marx, M. A. Azaquinazoline pan-KRAS Inhibitors, WIPO, WO2022132200 (2022)."},{"key":"71093_CR67","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41421-024-00699-4","volume":"10","author":"J Yang","year":"2024","unstructured":"Yang, J. et al. A pan-KRAS degrader for the treatment of KRAS-mutant cancers. Cell Discov. 10, 70 (2024).","journal-title":"Cell Discov."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71093-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71093-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71093-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:03:32Z","timestamp":1779149012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71093-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71093"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71093-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4425"}}